Pharmaceutical

Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy

An open-label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.

Dec 5, 2024 - 06:00
Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy
An open-label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.
Read the original article

Tags:

Previous Article

CEO of UnitedHealthcare, Brian Thompson, shot dead in New York City

Next Article

Maze Therapeutics raises $115m to advance kidney disease candidates

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanofi and Orano Med link for radioligand therapy development

Sanofi and Orano Med link for radioligand therapy devel...

Oct 20, 2024

STAT+: FDA’s Califf talks cell and gene therapies, abortion pill, Alzheimer’s drugs

STAT+: FDA’s Califf talks cell and gene therapies, abor...

Apr 19, 2023

Stéphane Bancel, Bernie Sanders spar over what Moderna owes the federal government

Stéphane Bancel, Bernie Sanders spar over what Moderna ...

Mar 22, 2023